Main menu

Akira Matsuno is the President, Chief Financial Officer, and Co-Founder of Tune Therapeutics.

An accomplished biotech executive with a background in cell & gene therapies, Akira was previously CFO and Head of Corporate Development at Lyell Immunopharma, where he led multiple private fundraising rounds, strategic alliances, and a global R&D collaboration.

Prior to Lyell, he was the global NEX-T Platform Program Lead at Juno Therapeutics, focused on the development of a next-generation cell therapy manufacturing process and multiple drug candidates. As Vice President of Finance, he led the strategic planning, FP&A and treasury organizations, and led negotiations on multiple executed transactions, including academic partnerships, industry collaborations, and acquisitions. He is also the Co-Founder of JW Therapeutics, a cell therapy company based in China. Across these roles, Akira has executed over $50BN in financing and strategic transactions – including over $2BN in equity-related transactions. Previously, Akira was a late-stage private equity investment professional at Vulcan Capital, and started his career at Lehman Brothers, in its investment banking division.

He received his B.S. in Finance and Management from the Wharton School of University of Pennsylvania.